

( (S (NP-SBJ Two Japanese scientists)
     (VP said
         (SBAR 0
               (S (NP-SBJ they)
                  (VP discovered
                      (NP (NP an antibody)
                          (SBAR (WHNP-1 that)
                                ,
                                (S (PP-LOC in
					   (NP laboratory test-tube experiments))
                                   ,
                                   (NP-SBJ-2 *T*-1)
                                   (VP kills
                                       (NP AIDS-infected cells)
				       (SBAR-TMP while
						 (S (NP-SBJ *-2)
						    (VP preserving
							(NP healthy cells))))))))))))
     .))
( (S (SBAR-ADV If
	       (S (NP-SBJ further experiments)
		  (VP are
		      (ADJP-PRD successful))))
     ,
     (NP-SBJ the work)
     (VP would
         (VP represent
             (NP (NP a major advance)
                 (PP in
                     (NP (NP research)
                         (PP on
                             (NP acquired immune deficiency syndrome)))))))
     .))
( (S (NP-SBJ-1 (NP The drug
		   AZT)
	       ,
	       (NP (NP the only treatment)
		   (RRC (ADVP-TMP currently)
			(PP on
			    (NP the market))))
	       ,)
     (VP claims
         (S (NP-SBJ-3 *-1)
	    (VP (ADVP only)
		(VP to
		    (VP help
			(S (NP-SBJ *-3)
			   (VP stop
			       (NP (NP the spread)
				   (PP of
				       (NP AIDS)))))))
		, not
		(VP to
		    (VP cure
			(NP it))))))
     .))
( (S But
     (NP-SBJ (NP (NP several analysts)
                 and
                 (NP Japanese scientists))
             (ADJP familiar
                   (PP with
                       (NP (NP the study)
                           ,
                           (SBAR (WHNP-2 which)
                                 (S (NP-SBJ-1 *T*-2)
                                    (VP was
                                        (VP announced
                                            (NP *-1)
                                            (PP-LOC at
						    (NP (NP a conference)
							(PP-LOC in
								(NP Nagoya))))
					    (NP-TMP yesterday)))))
                           ,))))
     (VP expressed
         (NP skepticism)
	 (PP-CLR over
		 (NP (NP the significance)
		     (PP of
			 (NP the results)))))
     .))
( (S And
     (NP-SBJ (NP the researchers)
             (NP themselves))
     (VP acknowledged
         (SBAR 0
               (S (NP-SBJ they)
                  (ADVP still)
                  (VP must
                      (VP do
                          (NP (ADJP much more)
                              work)
			  (SBAR-TMP before
				    (S (NP-SBJ they)
				       (VP can
					   (VP say
					       (SBAR whether
						     (S (NP-SBJ the treatment)
							(VP would
							    (ADVP actually)
							    (VP cure
								(NP humans))))))))))))))
     .))
( (S (NP-SBJ (NP Shin Yonehara)
             ,
             (NP (NP a research scientist)
                 (PP-LOC at
			 (NP (NP the Tokyo Metropolitan Institute)
			     (PP of
				 (NP Medical Science)))))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the antibody)
                          (SBAR (WHNP-2 0)
                                (S (NP-SBJ he)
                                   (VP discovered
                                       (NP *T*-2)))))
                  (VP works
                      (PP-MNR by
			      (S-NOM (NP-SBJ *)
				     (VP recognizing
					 (NP (NP an antigen)
					     (VP called
						 (S (NP-SBJ *)
						    (NP-PRD a Fas-antigen)))
					     ,
					     (SBAR (WHNP-1 which)
						   (S (NP-SBJ *T*-1)
						      (VP is
							  (ADJP-PRD characteristic
								    (PP of
									(NP an infected cell))))))))))))))
     .))
( (S (NP-SBJ The antibody)
     (ADVP-TMP then)
     (VP kills
         (NP the cell))
     .))
( (S (NP-SBJ (NP Dr. Yonehara)
             and
             (NP (NP his partner)
                 ,
                 (NP (NP Nobuyuki Kobayashi)
                     (PP of
                         (NP Yamaguchi University)))
                 ,))
     (VP said
         (SBAR 0
               (S (NP-SBJ their experiments)
                  (VP showed
                      (SBAR that
                            (S (NP-SBJ the antibody)
                               (VP wiped 
				   (PRT out)
                                   (NP (NP an average)
                                       (PP of
                                           (NP (NP 60 %)
                                               (PP of
                                                   (NP AIDS-infected cells)))))
				   (PP-TMP within
					   (NP three days)))))))))
     .))
( (S (S-TPC-1 (PP-LOC In
		      (NP (NP some)
			  (PP of
			      (NP the experiments))))
	      ,
	      (NP-SBJ it)
	      (VP killed
		  (NP (QP almost all) the infected cells)))
     ,
     (NP-SBJ the researchers)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (ADVP Meanwhile)
     ,
     (NP-SBJ-1 (NP (QP fewer
		       than
		       10) %)
	       (PP of
		   (NP the healthy cells)))
     (VP were
         (VP killed
             (NP *-1)))
     .))
( (S (NP-SBJ The two)
     (VP said
         (SBAR 0
               (S (NP-SBJ they)
                  (VP must
                      (VP (VP (ADVP still)
                              do
                              (NP more laboratory tests))
                          ,
                          then
                          (VP experiment
                              (PP-CLR on
				      (NP animals))))))))
     .))
( (S (NP-SBJ They)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 they)
                  (VP hoped
                      (S (NP-SBJ *-1)
                         (VP to
                             (VP conduct
                                 (NP tests)
                                 (PP-CLR on
					 (NP (NP human patients)
					     (PP-LOC in
						     (NP the U.S.))))
				 (PP-TMP by
					 (NP late next year)))))))))
     .))
( (S (S-TPC-2 (NP-SBJ-1 Japan)
	      (VP does n't
		  (VP have
		      (NP enough AIDS patients
			  (S (NP-SBJ *-1) 
			     (VP to
				 (VP do
				     (NP significant experimentation)
				     (PP-LOC in
					     (NP that country)))))))))
     ,
     (NP-SBJ they)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (NP-SBJ The announcement)
     (VP (VP got
             (NP wide exposure)
             (PP-LOC in
		     (NP the Japanese media)))
         , and
	 (VP (ADVP even)
	     moved
             (NP some pharmaceutical stocks)
             (NP-TMP yesterday)))
     .))
( (S But
     (NP-SBJ (NP Takashi Kitamura)
             ,
             (NP (NP (NP director)
                     (PP of
                         (NP (NP the biology department)
                             (PP-LOC at
				     (NP (NP (NP Japan 's)
					     National Institute)
					 (PP of
					     (NP Health)))))))
                 and
                 (NP (NP secretary)
                     (PP of
                         (NP (NP the government 's)
                             AIDS-research center))))
             ,)
     (VP said , ``
         (S (NP-SBJ I)
            (VP 'm not
                (ADJP-PRD so optimistic
                          (PP of
                              (NP (NP its future use)
                                  (PP-LOC in
					  (NP therapeutic methods))))))))
     . ''))
( (S (NP-SBJ He)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 some infected cells)
                  (VP (VP may not
			  (VP have
			      (NP the relevant antigen)))
		      and 
		      (VP (ADVP so)
			  would n't
			  (VP be
			      (VP killed
				  (NP *-1)
				  (PP-TMP (ADVP even) 
					  after
					  (NP (NP exposure)
					      (PP to
						  (NP the antibody)))))))))))
     .))
( (SINV ``
	(S-TPC-2 (NP-SBJ-1 The results)
		 (VP seem
		     (S (NP-SBJ *-1)
			(VP to
			    (VP be
				(ADJP-PRD very premature))))))
	, ''
	(VP said
	    (S *T*-2))
	(NP-SBJ (NP Mitsuru Miyata)
		,
		(NP (NP editor)
		    (PP of
			(NP (NP Nikkei Biotechnology)
			    ,
			    (NP a leading Japanese industry newsletter)))))
	.))
( (S (NP-SBJ Dr. Kobayashi)
     (VP responded
         (SBAR that
               (S (NP-SBJ he)
                  (VP thought
                      (SBAR 0
                            (S (NP-SBJ the antibody)
                               (VP could
                                   (ADVP potentially)
                                   (VP kill
                                       (NP all infected cells)))))))))
     .))
( (S But
     (NP-SBJ (NP he)
             and
             (NP Dr. Yonehara))
     (VP said
         (SBAR 0
               (S (NP-SBJ there)
                  (VP were
                      (ADVP still)
                      (NP-PRD (NP several uncertainties)
			      ,
			      (RRC (ADVP particularly)
				   (PP regarding
				       (NP possible side effects))))))))
     .))
( (SINV ``
	(S-TPC-1 (S (NP-SBJ Our antibody)
		    (VP (ADVP specifically)
			killed
			(NP infected cells)
			(PP-MNR at
				(NP a
				    (ADJP very low)
				    dose))))
		 , but
		 (S (NP-SBJ it)
		    (VP can
			(ADVP also)
			(VP kill
			    (NP other cells)))))
	, ''
	(VP said
	    (S *T*-1))
	(NP-SBJ Dr. Yonehara)
	.))
( (S ``
     (NP-SBJ We)
     (VP do n't
         (VP know
             (NP (NP the effect)
                 (PP of
                     (NP our antibody))
                 (PP on
                     (NP the human body)))))
     . ''))
( (S (S (NP-SBJ-1 AIDS)
        (VP is n't
            (VP considered
		(S (NP-SBJ *-1)
		   (NP-PRD (NP a widespread problem)
			   (PP-LOC in
				   (NP Japan)))))))
     --
     (S (NP-SBJ the government)
        (VP reports
            (NP (NP (QP about 1,000) known carriers)
                (PP of
                    (NP the virus)))))
     -- but
     (S (NP-SBJ-2 many companies)
        (VP have
            (VP poured
                (NP substantial resources)
                (PP-CLR into
			(NP research))
		(PP-TMP in
			(NP recent years))
		,
		(S-ADV (NP-SBJ-3 *-2)
		       (VP hoping
			   (S (NP-SBJ *-3)
			      (VP to
				  (VP cash 
				      (PRT in)
				      (PP-CLR on
					      (NP a possible cure))))))))))
     .))
( (S (NP-SBJ Dr. Kitamura)
     (VP said
         (SBAR (SBAR 0
                     (S (NP-SBJ (QP about 35) projects)
                        (VP are
                            (ADVP-TMP currently)
                            (PP-PRD under
                                    (NP way))
			    (PP-LOC in
				    (NP Japan)))))
               , and
               (SBAR that
                     (S (NP-SBJ (NP Japanese researchers)
                                (PP-TMP in
					(NP the past year)))
                        (VP have
                            (VP made
                                (S (ADJP-PRD available
					     (PP *ICH*-1)
					     (PP *ICH*-2))
				   (NP-SBJ three possible cures)
				   (PP-1 to
					 (NP American researchers))
				   (PP-2 for
					 (NP clinical tests)))))))))
     .))
( (S (NP-SBJ He)
     (VP said
         (SBAR that
               (S (SBAR-TMP (WHADVP-1 when)
			    (S (NP-SBJ (NP scientists)
				       (PP from
					   (NP the two countries)))
			       (VP meet
				   (ADVP again)
				   (PP-TMP in
					   (NP January))
				   (PP-LOC in
					   (NP New Orleans))
				   (ADVP-TMP *T*-1))))
                  ,
                  (NP-SBJ the Japanese)
                  (VP will
                      (VP present
                          (NP (ADJP (QP at
					least
					three) more) drugs)
                          (PP-CLR for
				  (NP human testing)))))))
     .))
( (S (NP-SBJ AZT)
     (VP is
         (NP-PRD (NP (NP the world 's)
                     only prescription medicine)
                 (VP approved
                     (NP *)
                     (PP-CLR for
			     (S-NOM (NP-SBJ *)
				    (VP treating
					(NP the disease)))))))
     .))
( (S (NP-SBJ (NP Wellcome PLC)
             ,
             (NP a major British pharmaceutical maker)
             ,)
     (VP sells
         (NP the drug)
         (PP-MNR under
		 (NP (NP the name)
		     (NP Retrovir))))
     .))
( (S (NP-SBJ-1 A Wellcome spokesman)
     (VP declined
         (S (NP-SBJ *-1)
            (VP to
                (VP comment
                    (PP-CLR on
			    (NP (NP the discovery)
				(PP of
				    (NP the antibody))
				(PP-LOC in
					(NP Japan))))))))
     .))
( (S But
     (NP-SBJ (NP Andrew Porter)
             ,
             (NP (NP a drug-industry analyst)
                 (PP-LOC at
			 (NP (NP Nikko Securities Co.)
			     (PP-LOC in
				     (NP London)))))
             ,)
     (VP said
         (SBAR 0
               (S (SBAR-ADV if
			    (S (NP-SBJ-2 the product)
			       (VP were
				   (S (NP-SBJ-1 *-2) 
				      (VP to
					  (VP be
					      (VP (ADVP-MNR successfully)
						  developed
						  (NP *-1))))))))
                  (NP-SBJ it)
                  (VP would
                      (VP represent ``
                          (NP (NP a potential threat)
                              (PP to
                                  (NP (NP the long-term viability)
                                      (PP of
                                          (NP Retrovir))))))))))
     .))
